BOTULINUM B TOXIN
Stroke Disorder
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
127 Active assets in the Stroke Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
INCOBOTULINUMTOXINA Parc de Salut Mar | Phase 4 | BBB |
Aggrenox Boehringer Ingelheim | Phase 4 | BBB |
ATENOLOL Northern California Institute of Research and Education | Phase 4 | BBB |
Dextromethorphan University of Florida | Phase 4 | BBB |
Tenecteplase Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
BOTULINUM B TOXIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →